Name | Propafenone HCl |
Synonyms | sa79 SA 79 wz884 WZ 884 Pronon Rythmol Arythmol Rytmonorm Fenoprain rytmonorm Rythmol SR Baxarytmon Rhythmonorm Propafenone HCl UNII-33XCH0HOCD PROPAFENONE HCL Propafenon hydrochlorid Propafenone hydrochloride Propafenon hydrochlorid [German] 2'-(2-Hydroxy-3-(propylamino)propoxy)-3-phenylpropiophenone hydrochloride Propiophenone, 2'-(2-hydroxy-3-(propylamino)propoxy)-3-phenyl-, hydrochloride 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one hydrochloride 1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenylpropan-1-one hydrochloride 1-[2-(2-HYDROXY-3-[PROPYLAMINO]-PROPOXY)PHENYL]-3-PHENYL-1-PROPANONE HYDROCHLORIDE 1-Propanone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-, hydrochloride |
CAS | 34183-22-7 |
EINECS | 251-867-9 |
InChI | InChI=1/C21H27NO3.ClH/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17;/h3-11,18,22-23H,2,12-16H2,1H3;1H |
Molecular Formula | C21H28ClNO3 |
Molar Mass | 377.9 |
Melting Point | 165-1670C |
Boling Point | 519.6°C at 760 mmHg |
Flash Point | 268°C |
Solubility | Soluble in methanol (50 mg/ml), water(slightly soluble in cold water), ethanol, acetone |
Vapor Presure | 1.27E-11mmHg at 25°C |
Appearance | neat |
Color | White to Off-White |
Maximum wavelength(λmax) | ['303nm(MeOH)(lit.)'] |
Merck | 14,7794 |
Storage Condition | 2-8°C |
Physical and Chemical Properties | Character: white crystalline powder, odorless, bitter. This product is slightly soluble in ethanol, chloroform or glacial acetic acid, and slightly soluble in water. |
Use | For the prevention and treatment of ventricular or supraventricular ectopic tachycardia, tachycardia, pre-excitation syndrome and the prevention of ventricular fibrillation after shock cardioversion |
Risk Codes | R46 - May cause heritable genetic damage R22 - Harmful if swallowed |
Safety Description | S53 - Avoid exposure - obtain special instructions before use. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
WGK Germany | 3 |
RTECS | UH2833000 |
HS Code | 2922504500 |
Toxicity | LD50 in rats (mg/kg): 18.8 i.v.; 700 orally (Hapke, Prigge) |
This product is 3-phenyl-l-[2-[3-(propy1)-2-cyclopropoxy] phenyl]-1-acetone hydrochloride. The content of C21H27N03 • HC1 shall not be less than 99.0% calculated as dry product.
The melting point of this product (General 0612) is 171~174°C.
take 0.10g of this product, add 20ml of methanol, heat and dissolve in a water bath at about 60°C, let it cool, and the solution should be clear; If it is turbid, compared with No. 1 turbidity standard solution (General Principles 0902 first method), should not be more concentrated.
take this product, add an appropriate amount of acetonitrile to dissolve, dilute with mobile phase to prepare a solution containing about 1mg of Propafenone Hydrochloride in each lml as a test solution; Take an appropriate amount for precision measurement, A solution containing about 1mg per 1 ml was prepared as a control solution by quantitative dilution with the mobile phase. According to the high performance liquid chromatography (General 0512) test, using octanosilane bonded silica gel as filler, 0.0015mol/L dipotassium hydrogen phosphate (adjusted to pH 2.5 with phosphoric acid)-acetonitrile (65:35) as mobile phase; The detection wavelength was 220nm. The number of theoretical plates shall not be less than 2000 based on the Propafenone peak. 10 u1 of the test solution and the control solution were respectively injected into the human liquid chromatograph, and the chromatogram was recorded to 4 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (0.1% ) , the sum of each impurity peak area shall not be greater than 3 times (0.3%) of the main peak area of the control solution.
take about 0.2g of this product, precision weighing, top empty bottle, Precision Add dimethyl sulfoxide 5ml to dissolve, seal, as a test solution; Another methanol, ethanol, an appropriate amount of acetone and ethyl acetate, precision weighing, quantitative dilution with dimethyl sulfoxide to make a solution containing about 0.12mg of methanol and 0.2mg of ethanol, propanol and ethyl acetate in each lml, precision measuring 5ml, top empty bottle, sealed, as a control solution. Test as residual solvent assay (General 0861 second method). (5%) phenyl-( 95%) methyl polysiloxane (or polar similar) as the fixing liquid; The initial temperature is 40°C, maintained for 7 minutes, at a rate of 8°C per minute to 120°C, it was maintained for 15 minutes; The inlet temperature was 200°C; The detector temperature was 250X:; The headspace bottle equilibration temperature was 90°C and the equilibration time was 30 minutes. Take the reference solution into the headspace, the separation degree between the peaks of each component shall meet the requirements. Then the sample solution and the reference solution were injected with headspace, and the chromatogram was recorded. According to the external standard method to calculate the peak area, methanol, ethanol, acetone and ethyl acetate residues should be in accordance with the provisions.
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
take 2.0g of this product and check it according to law (General rule 0841). The remaining residue shall not exceed 0.1%.
The residue left under the item of ignition residue shall not be more than 10 parts per million (ppm) and shall be inspected according to law (General rule 0821 second law).
take this product about 0.3g, precision weighing, add anhydrous formic acid 2ml to dissolve, add acetic anhydride 50ml, according to the potential titration method (General rule 0701), immediately with perchloric acid titration solution (0.1 mol/L) titration, and the results of the titration were corrected with a blank test. Each 1 ml of perchloric acid titration solution (0.1 mol/L) corresponds to 37.79mg of C21H27N03. Hc1.
antiarrhythmic drugs.
light shielding, sealed storage.
This product contains Propafenone Hydrochloride (C21H27N03 • HCI) should be 93.0% to 107.0% of the label.
This product is white or off-white.
Take 20 tablets of this product, precise weighing, fine grinding, precise weighing appropriate amount (about 50mg equivalent to Propafenone Hydrochloride), put it in a 100ml measuring flask, add appropriate amount of ethanol, shake to dissolve Propafenone Hydrochloride, add ethanol to dilute to the scale, shake, filter, take a precise amount of filtrate to continue 5ml, 100ml flask, add ethanol to dilute to the scale, shake. The absorbance was measured at a wavelength of 0401 NM according to UV-Vis spectrophotometry (General Rule 220), and the absorption coefficient of C21H27N03 · HCl was calculated.
Same as Propafenone Hydrochloride.
(l ) 50mg (2) lOOmg (3)150mg
light shielding, sealed storage.
This product is a sterile aqueous solution of Propafenone Hydrochloride. Propafenone Hydrochloride (C21H27N03 • HCl) shall be present in an amount of 90.0% to 110.0% of the label amount.
This product is a clear colorless liquid.
take an appropriate amount of this product, and quantitatively dilute it with ethanol to a solution containing about 20ug of Propafenone Hydrochloride per lml, according to ultraviolet-visible spectrophotometry (General rule 0401 ), the absorbance was measured at a wavelength of 248nm and calculated as the absorption coefficient of C21H27N03. HCl was 220.
Same as Propafenone Hydrochloride.
(l)5ml:17.5mg (2)5ml:35mg (3)10ml:35mg (4)20ml:70mg
light shielding, closed storage.
This product contains Propafenone Hydrochloride (C21H27N03 • HCl) should be 90.0% ~ 110.0% of the label amount.
should comply with the relevant provisions under the capsule (General rule 0103).
take the contents under the difference of loading amount, mix evenly, accurately weigh an appropriate amount (about 20mg equivalent to Propafenone Hydrochloride), put it in a 100ml children's bottle, and add an appropriate amount of ethanol, shake to dissolve Propafenone Hydrochloride (if necessary, heat it in a warm water bath and let it dissolve and then let it cool), dilute to the scale with ethanol, shake well, filter, and take 5ml of continued filtrate with precision, put 50ml measuring flask, add ethanol to dilute to the scale, shake. The absorbance was measured at a wavelength of 0401 NM according to UV-Vis spectrophotometry (General Rule 220), and the absorption coefficient of C21H27N03 · HCl was calculated.
Same as Propafenone Hydrochloride.
(l)100mg (2)150mg
light shielding, sealed storage.
pharmacological effects | 1. propafenone hydrochloride is an Ic sodium channel blocker and is a broad-spectrum antiarrhythmic drug. The experimental results in isolated animal myocardium show that 0.5~1 μg/min can reduce the depolarization of systolic phase, thus prolonging conduction, slightly prolonging the duration of action potential and effective refractory period, and can increase the threshold potential of myocardial cells, significantly reducing the spontaneous excitability of myocardium. It not only acts on the atrium and ventricle (mainly affects Pujinye fibers, but has little effect on the myocardium), but also acts on the formation and conduction of excitement. Clinical data show that the therapeutic dose (300mg orally and 30mg intravenously) can reduce myocardial stress, the effect is lasting, PQ and QRS are increased, and the effective refractory period of atrium and atrioventricular node is prolonged. It has an antagonistic effect on various types of experimental arrhythmia. The antiarrhythmic effect is related to its membrane stabilizing effect and competitive beta blocking effect. It still has a weak calcium antagonism (100 times weaker than verapamil), and has a mild myocardial inhibition effect, increasing end-stage diastolic blood pressure, and reducing stroke volume. Its effects are all proportional to the dose of the drug. It also has a mild effect of lowering blood pressure and slowing heart rate. 2. In vitro experiments show that propafenone can relax coronary artery and bronchial smooth muscle. 3. It has a local anesthetic effect similar to that of procaine. 4. Renal dysfunction occurred after 6 months of oral administration of 180~360(mg/kg)/day (12~24 times of the maximum recommended dose for adults) in rats, with inflammatory and non-inflammatory reactions in renal tubules and interstitium. Liver steatosis can be found when long-term rats are given 19 times the maximum recommended dosage for adults. |
indication | is used for the prevention of paroxysmal ventricular tachycardia, paroxysmal supraventricular tachycardia and preexcitation syndrome with supraventricular tachycardia, atrial flutter or atrial fibrillation. It can also be used for the treatment of various premature beats. |
pharmacokinetics | 1. the binding rate of this product to plasma protein is as high as 93%, and the bioavailability will be improved when the dose is increased. 2. The decline of liver function will also increase the bioavailability of drugs, and the clearance of propafenone will slow down when severe liver function is damaged. 3. The pharmacokinetic curve of propafenone is nonlinear. The half-life of the drug is 3.5~4 hours. This product is excreted by the kidneys, mainly metabolites, and a small part (<1%) is the original substance. 4. It cannot be drained through dialysis. |
original research and reference preparations | 1. original research: first developed by Knoll Pharma and listed in Italy in 1983, with Rytmonorm trade names, tablets, specifications of 150mg and 300mg. It was subsequently listed in Germany, Japan (100mg and 150mg) and the United States. In 2001, Abbott Pharmaceuticals acquired Knoll Pharma and obtained the Rytmonorm holding rights. 2. FDA:RYTHMOL, GLAXO SMITH KLINE LLC,300 mg3, UK: PROPAFENONE NRIM 150MG TABLETS,150, 300mg, NRIM LIMITED MARLBOROUGH HOUSE4, Japan: Pronon Tab. 100mg, 150mg, TOA EIYO LTD. 5. domestic import situation (1) import: trade name yuefulong, specification 150mg, Abbott production (2) import localization: no |
drug interaction | combined with quinidine can slow down the metabolic process. The combination with local anesthetics can increase the occurrence of side effects of the central nervous system. Propafenone can increase serum digoxin concentration and is dose-dependent. The combination with propranolol and metoprolol can significantly increase its plasma concentration and clearance half-life, but has no effect on propafenone. When combined with warfarin, it can increase warfarin blood concentration and prothrombin time. The combination with cimetidine increased the blood steady-state level of propafenone, but had no effect on its electrophysiological parameters. |
biological activity | Propafenone HCl is a typical antiarrhythmic drug used to treat diseases related to rapid heartbeat, such as atrial and ventricular arrhythmia. |
Target | Value |
use | used to prevent and treat ventricular or supraventricular ectopic hyperactivity, tachycardia, preexcitation syndrome and prevention of ventricular fibrillation after electric shock cardioversion etc. used to prevent and treat ventricular or supraventricular ectopic hyperactivity, tachycardia, preexcitation syndrome and prevention of ventricular fibrillation after electric shock cardioversion etc. |